Anti-human GPR87 (Extracellular) Recombinant Monoclonal Antibody (HM0059)
Price range: $230.00 through $720.00
Anti-human GPR87 Recombinant Monoclonal Antibody (HM0059) is a high-affinity recombinant monoclonal antibody generated by phage-display selection from a mouse-derived antibody library, followed by structure-guided affinity optimization. The antibody recognizes an epitope (AA 2-23) located within the N-terminal extracellular flexible region of G protein-coupled receptor 87 (GPR87). It has been validated by ELISA using a recombinant epitope-Fc fusion antigen, by Western blot against a recombinant MBP-epitope fusion protein, and by Western blot detection of endogenous GPR87 protein in human cell lysates.
Also known as: hGPR87, GPR87, GPR95, and G-protein coupled receptor 87.
For research use only. Not for diagnostic or therapeutic applications.
Product Information
| Property | Description |
|---|---|
| Product Name | Anti-human GPR87 Recombinant Monoclonal Antibody |
| Antibody ID | HM0059 |
| Target Protein | G-protein coupled receptor 87 |
| Target Protein Short Name | hGPR87 |
| UniProt Accession | Q9BY21 (human) |
| Molecular Weight | 41.4 kDa |
| Antibody Type | Recombinant monoclonal antibody |
| Host Species | Mouse |
| Recombinant Format | Full-length mouse IgG1 |
| Isotype | Mouse IgG1 |
| Species Reactivity | Human |
| Tested Applications | WB |
| Recommended Dilution for WB | 1:500–1:5000 |
| Antigen | Recombinant epitope-Fc fusion protein |
| Epitope Sequence | GFNLTLAKLPNNELHGQESHNS |
| Expression System | HEK293 cells |
| Purification | Protein G affinity chromatography |
| Conjugate | Unconjugated |
| Concentration | 0.1 mg/mL |
| Storage Buffer | 0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7 |
| Storage Condition | Store at -20°C |
| Research Use | For research use only. Not for diagnostic or therapeutic applications |
Product Background
G-protein coupled receptor 87 (GPR87) is an orphan G protein-coupled receptor implicated in cell proliferation, survival signaling, tumor progression, epithelial biology, and stress-response pathways. GPR87 has attracted increasing research interest due to its association with multiple cancer types and its potential role in p53-regulated signaling networks.
GPR87 is widely studied in cancer biology, GPCR signaling, epithelial cell biology, drug discovery, and receptor-mediated signaling research.
Antibody Development
HM0059 was generated by phage-display selection using a mouse-derived antibody library. Recombinant epitope-Fc fusion protein containing the GPR87 epitope sequence was used as the selection antigen. Following identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.
The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.
Binding and specificity were evaluated by:
- ELISA using recombinant epitope-Fc fusion antigen
- Western blot detection of endogenous full-length GPR87 protein
Validation Data
ELISA Validation
ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc-only control protein.
Validation conditions:
- Well 1: Fc control protein
- Well 2: Epitope-Fc fusion protein
- Detection substrate: TMB
Note:
ELISA validation confirms binding to epitope-Fc fusion antigen. Full-length protein binding in solution has not been tested by ELISA.
Western Blot Validation – Recombinant Fusion Protein
Western blot analysis demonstrated specific recognition of recombinant MBP-epitope fusion protein expressed in BL21(DE3) cells, while no significant binding was observed against MBP control protein.
Validation conditions:
- Lane 1: MBP control protein
- Lane 2: MBP-epitope fusion protein
- Standard reducing Western blot
Western Blot Validation – Endogenous Full-Length Protein
Endogenous human GPR87 protein was detected in human cell lysates under reducing Western blot conditions.
Validated samples:
- 293T cells
- HeLa cells
- HepG2 cells
Observed bands:
- Major immunoreactive bands were detected around approximately 30–35 kDa.
- Additional higher molecular weight bands around approximately 70 kDa were also observed in liver and intestine samples, potentially representing glycosylated forms, receptor-associated complexes, or oligomeric species.
Detection condition:
- Standard reducing Western blot
- HRP-conjugated anti-mouse secondary antibody
| Size | 20 ul, 100 ul |
|---|
Related products
